Risk of active tuberculosis and herpes zoster with tumor necrosis factor inhibitor treatment in adults with autoimmune disease conditions: a systematic trial sequential analysis of randomized placebo-controlled clinical trials

George N. Okoli, Benjamin J. Cowling, Nicole Askin, Diane M. Harper, Paul Van Caeseele

Open source

DOI
10.1080/14740338.2026.2642872
Published
2026-03-11
Container
Expert Opinion on Drug Safety
Publisher
Informa UK Limited
Open access
unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1080/14740338.2026.2642872,
  title = {Risk of active tuberculosis and herpes zoster with tumor necrosis factor inhibitor treatment in adults with autoimmune disease conditions: a systematic trial sequential analysis of randomized placebo-controlled clinical trials},
  author = {George N. Okoli and Benjamin J. Cowling and Nicole Askin and Diane M. Harper and Paul Van Caeseele},
  year = {2026},
  journal = {Expert Opinion on Drug Safety},
  doi = {10.1080/14740338.2026.2642872},
  url = {https://doi.org/10.1080/14740338.2026.2642872}
}

RIS

TY  - JOUR
TI  - Risk of active tuberculosis and herpes zoster with tumor necrosis factor inhibitor treatment in adults with autoimmune disease conditions: a systematic trial sequential analysis of randomized placebo-controlled clinical trials
AU  - George N. Okoli
AU  - Benjamin J. Cowling
AU  - Nicole Askin
AU  - Diane M. Harper
AU  - Paul Van Caeseele
PY  - 2026
JO  - Expert Opinion on Drug Safety
DO  - 10.1080/14740338.2026.2642872
UR  - https://doi.org/10.1080/14740338.2026.2642872
ER  - 

APA

Okoli, G. N., Cowling, B. J., Askin, N., Harper, D. M., & Caeseele, P. V. (2026). Risk of active tuberculosis and herpes zoster with tumor necrosis factor inhibitor treatment in adults with autoimmune disease conditions: a systematic trial sequential analysis of randomized placebo-controlled clinical trials. Expert Opinion on Drug Safety. https://doi.org/10.1080/14740338.2026.2642872

Source records